Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): Results from a physician survey

Journal of Comparative Effectiveness Research

Volumn 1, Issue 5, 2012, Pages 453-463

  Dekoven, Mitch ^a   Bonthapally, Vijayveer ^b   Jiao, Xiaolong ^a   Ganguli, Arijit ^b   Pathak, Prathamesh ^a   Lee, Won Chan ^a   Ray, Saurabh ^b  

^a IQVIA   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

biomarkers; breast cancer; metastatic; physician survey; treatment patterns

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GEMCITABINE; LAPATINIB; LETROZOLE; MEGESTROL; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; DATA BASE; DRUG CHOICE; DRUG UTILIZATION; FRANCE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SPAIN; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNITED KINGDOM;

EID: 84886943415     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.12.43     Document Type: Article

References (24)

1. American Cancer Society. Breast Cancer Facts and Figures 2011-2012. American Cancer Society, GA, USA (2011).
2. Downs-Holmes C, Silverman P. Breast cancer: Overview and updates. Nurse Pract. 36(12), 20-26 (2011).
3. Gokmen-Polar Y, Nakshatri H, Badve S. Biomarkers for breast cancer stem cells: The challenges ahead. Biomark. Med. 5(5), 661-671 (2011).
4. Fernandex Y, Cueva J, Palomo AG et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat. Rev. 36(1), 33-42 (2010).
5. Howard JH, Bland KI. Current management and treatment strategies for breast cancer. Curr. Opin. Obstet. Gynecol. 24(1), 44-48 (2011).
6. Dewis R, Gribbin J. National Institute for Health and Clinical Excellence: GUIDANCE. National Collaborating Centre for Cancer, Cardiff, UK (2009).
7. Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist 16(9), 1203-1214 (2011).
8. Inoue Y, Toiyama Y, Tanaka K, Miki C, Kusunoki M. A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy. Jpn J. Clin. Oncol. 39(6), 367-375 (2009).
9. Jonsson B, Wilking N. The effect of cancer drug vintage on cancer survival and mortality. Ann. Oncol. 18(Suppl. 3), iii67-iii77 (2007).
10. Inoue Y, Toiyama Y, Tanaka K, Uchida K, Mohri Y, Kusunoki M. Oncology market research provides a feasible index for standardization of colorectal cancer chemotherapy. Jpn J. Clin. Oncol. 41(10), 1203-1208 (2011).
11. Zhao Z, Pelletier E, Barber B et al. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Curr. Med. Res. Opin. 28(2), 221-229 (2012).
12. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: Differences in tumor biology from European- American women. Cancer Res. 66(17), 8327-8330 (2006). (Pubitemid 44449138)
13. Telli ML, Kurian AW, Chang ET, Keegan TH, Ford JM, Gomez SL. Asian race and breast cancer subtypes: A study from the California Cancer Registry. J. Clin. Oncol. 26(15), 6618 (2008).
14. Li CI, Malone KE, Daling Jr. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol. Biomarkers Prev. 7, 601-607 (2002). (Pubitemid 34760817)
15. Chu KC, Anderson WF, Fritz A et al. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92, 37-45 (2001). (Pubitemid 32623038)
16. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol. 22, 237-252 (2003
17. Ross JS, Fletcher JA Bloom KJ et al. Targeted therapy in breast cancer - The HER-2/new gene and protein. Mol. Cell. Proteomics 3, 379-398 (2004). (Pubitemid 38702091)
18. Cardoso F, Senkus-Konefka E, Fallowfield L et al. Locally recurrent or metastatic breast cancer: Esmo Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v15-v19 (2010).
19. ESMO MOSES Task Force. Medical Oncology Status in Europe Survey (MOSES): PHASE II. European Society for Medical Oncology, Lugano, Switzerland (2006).
20. Barrios CH, Sampaio C, Vinholes J, Caponero R. What is the role of chemotherapy in estrogen receptor positive, advanced breast cancer? Ann. Oncol. 20, 1157-1162 (2009).
21. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21(3), 242-252 (2012).
22. O'Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three Phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res. 69(Suppl.24), 207 (2009).
23. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366, 299-309 (2012).
24. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 366, 310-320 (2012).